Table 2 Data extraction form

ID

Valid PubMed ID number

Pubmed ID

Journal

Name of journal

Journal of publication

Year

2007–2018

Year of publication

Tumor site

Non-small cell lung cancer Melanoma Renal cell carcinoma Squamous cell carcinoma of the head and neck Urothelial carcinoma Classical Hodgkin lymphoma Other

The tumor type for which treatment with a check-point inhibitor was analyzed.

Check_point_1

Nivolumab

Name of the first check-point inhibitor being compared.

Pembrolizumab

Atezolizumab

Avelumab

Durvalumab

Ipilimumab

Tremelimumab

Check_point_2

Nivolumab

Name of 2nd check-point inhibitor being compared, if applicable.

Pembrolizumab

Atezolizumab

Avelumab

Durvalumab

Ipilimumab

Tremelimumab

Comparator_1

Placebo

Name of the 1st non-check-point-inhibitor agent or chemotherapeutic regimen being compared, if applicable.

Name of other agent or regimen

Comparator_2

Placebo

Name of the 2nd non-check-point-inhibitor agent or chemotherapeutic regimen being compared, if applicable.

Name of other agent or regimen

Funding

Industry/government

Funding source declared by article

Country

List of country names

List of all the countries in which the economic analysis applied as reported by the article.

Multiple_countries

Y/N

Did the economic analysis apply to multiple countries?

Title

C/I

As detailed in CHEERS recommendations [9]

Abstract

C/PC/I

As detailed in CHEERS recommendations [9]

Background & Objectives

C/PC/I

As detailed in CHEERS recommendations [9]

Target population

C/PC/I

As detailed in CHEERS recommendations [9]

Setting_Location

C/PC/I

As detailed in CHEERS recommendations [9]

Perspective

C/PC/I

As detailed in CHEERS recommendations [9]

Comparators

C/PC/I

As detailed in CHEERS recommendations [9]

Time horizon

C/PC/I

As detailed in CHEERS recommendations [9]

Discount rate

C/PC/I

As detailed in CHEERS recommendations [9]

Health outcomes

C/PC/I

As detailed in CHEERS recommendations [9]

Effectiveness

C/PC/I

As detailed in CHEERS recommendations [9]

Preference for outcomes

C/PC/I/NA

As detailed in CHEERS recommendations [9]

Resources and cost

C/PC/I

As detailed in CHEERS recommendations [9]

Resource quantities

C/PC/I

As detailed in CHEERS recommendations [9]

Choice of model

C/PC/I

As detailed in CHEERS recommendations [9]

Assumptions

C/PC/I

As detailed in CHEERS recommendations [9]

Analytic methods

C/PC/I

As detailed in CHEERS recommendations [9]

Study parameters

C/PC/I

As detailed in CHEERS recommendations [9]

ICERs

C/PC/I

As detailed in CHEERS recommendations [9]

Uncertainty

C/PC/I

As detailed in CHEERS recommendations [9]

Heterogeneity

C/PC/I/NA

As detailed in CHEERS recommendations [9]

Limitations

C/PC/I

As detailed in CHEERS recommendations [9]

Funding source

C/I

As detailed in CHEERS recommendations [9]

Conflict of Interest

C/I

As detailed in CHEERS recommendations [9]